The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Daily Roundup | Iovance Lung Data Points to a Subgroup & Ono Plans New Pain Studies After 3 Misses

October 29, 2026 edition, released October 30. The audio reflects the October 29 roundup; the INO-3107 watch refers to an October 30 FDA target date, not an announced dec

Daily Roundup | Genmab's Cancer Survival Gain & Lilly's Retatrutide Dose Trade-Off

This is the October 28 edition of The Pharma Closeout, released October 29. Genmab's investigational petosemtamab combination improves survival against pembrolizumab alo

Daily Roundup | Artiva Ends AlloNK, Cuts 94% of Staff & Ferring Agrees to Buy Gameto

Artiva ends AlloNK and cuts about 94% of staff after a risk-benefit review covering durability and two separately assessed deaths. Ferring agrees to acquire Gameto for up

Daily Roundup | BioNTech/DualityBio Breast ADC Gain Called Modest & Merck's sac-TMT Survival Edge Under FDA Review

October 26, 2026 edition, released October 27. Recorded October 26: references to today mean October 26, and tomorrow means October 27. BioNTech and DualityBio's breast

Week in Review | Amgen's Survival Gain, Roche's KRAS Challenge & Gilead's IBD Deal

Sunday, October 25 edition, released Monday, October 26 with the SANOVO update. Amgen's Imdelltra plus AstraZeneca's Imfinzi extended median survival to 21.1 months from

Daily Roundup | Remibrutinib Cuts MS Relapses & Iza-bren Improves Breast Cancer PFS

Delayed release on October 24, 2026 of the Friday, October 23 edition. News and relative-date references are as of October 23. Novartis's investigational remibrutinib cu

UEG Week 2026 Debrief: Takeda's Treat-to-Target Test & Duvakitug's 44-Week TL1A Read

The Pharma Closeout's UEG Week 2026 Debrief covers the readouts from United European Gastroenterology Week in Barcelona that matter for drug, device and payer strategy. T

Daily Roundup | Merck-Moderna mRNA Cuts Melanoma Recurrence or Death & AbbVie HS Drug Hits Phase 3 Goal

October 22, 2026 edition, released October 23. Reporting reflects the October 22 research cutoff. Merck and Moderna's investigational intismeran autogene, added to Keytr

Daily Roundup | Brepocitinib Holds Uveitis Control Off Steroids; Oral Olorofim Shows Far Fewer Kidney Events

October 21, 2026 edition, released October 22. Relative dates in the audio refer to October 21. Roivant's Priovant reports two positive Phase 3 trials of oral brepocitin

Daily Roundup | GSK's Hibsago Offers a Path Off Hepatitis B Treatment & Tezspire Details EoE Data

FDA approved GSK's Hibsago (bepirovirsen) for selected adults with chronic hepatitis B without cirrhosis, opening a possible path off long-term treatment after a staged t

Daily Roundup | GSK's Jemperli Wins Accelerated Approval & Disc's Bitopertin Meets Phase 3 Endpoints

FDA granted accelerated approval to GSK's Jemperli (dostarlimab) for biomarker-defined locally advanced rectal cancer, with continued surveillance required for responders

AAO 2026 Debrief: Retina's Durability Race & A Stargardt Pill Heads to an FDA Decision

The Pharma Closeout's AAO 2026 Debrief covers the readouts from the American Academy of Ophthalmology meeting in New Orleans that matter for drug, device and payer strate

Week in Review | Revita Slows Regain After Tirzepatide at Six Months; Liquidia Settles With United Therapeutics

Fractyl Health reports that its investigational Revita met the six-month co-primary endpoint of the double-blind, sham-controlled REMAIN-1 pivotal study in adults who los

Daily Roundup | Enspryng Approved for Thyroid Eye Disease as Home Injection & Omeros Refused Again by EU Panel

Friday, October 16 edition. Roche’s Enspryng wins FDA approval for thyroid eye disease as a home injection, while Omeros faces another negative European opinion for nars

Daily Roundup | Anktiva Expands Bladder Cancer Label & Vanda's Anxiety Trial Misses

FDA expanded ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) to papillary-only bladder cancer by extrapolating earlier evidence. Vanda paused VQW-765 after its

Daily Roundup | BioNTech's Cancer Trial Setback & Roche's Fat-Cell Bet

October 14, 2026 edition, released October 15, 2026. BioNTech's BNT113 missed progression-free survival in its pivotal head and neck cancer trial, leaving overall surviva

Daily Roundup | Bristol's Split IPF Result & RYZ101's Phase 3 Win

Monday, October 12, 2026 edition, released Tuesday, October 13, 2026. News checked through October 13, 2026; no material updates to the stories below were found. Bristol

Week in Review | AstraZeneca's $2B Summit Bet, Merck's Eye Trial & Roche's Vamikibart Filing

Merck's remigromig met BRUNELLO's noninferiority bar in diabetic macular edema, but showed no superiority and a notable safety imbalance. AstraZeneca completed its $2 bil

MDS 2026 Debrief: Two Genetic Bets Fall in Full Data & Juvmo Meets Its Payers

The Pharma Closeout's MDS 2026 Debrief covers the readouts from the International Parkinson and Movement Disorder Society congress in Seoul that matter for drug, diagnost

Daily Roundup | Hovilpri Wins FDA Approval & Biohaven Licenses BHV-1300 to Ono for $80M at Closing

Friday, October 9 edition, released late Saturday, October 10. FDA approved Hovilpri (pritelivir) for immunocompromised adults with stubborn herpes simplex lesions, but